Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Repeatability of 68Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume

Robert Seifert, Patrick Sandach, David Kersting, Wolfgang P. Fendler, Boris Hadaschik, Ken Herrmann, John J. Sunderland and Janet H. Pollard
Journal of Nuclear Medicine May 2022, 63 (5) 746-753; DOI: https://doi.org/10.2967/jnumed.121.262528
Robert Seifert
1Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital, Essen, Germany;
2West German Cancer Center, Essen, Germany;
3Department of Nuclear Medicine, University Hospital Münster, University of Münster, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Sandach
1Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital, Essen, Germany;
2West German Cancer Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Kersting
1Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital, Essen, Germany;
2West German Cancer Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang P. Fendler
1Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital, Essen, Germany;
2West German Cancer Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris Hadaschik
2West German Cancer Center, Essen, Germany;
4Department of Urology, University Hospital Essen, and German Cancer Consortium–University Hospital, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Herrmann
1Department of Nuclear Medicine, University of Duisburg–Essen and German Cancer Consortium–University Hospital, Essen, Germany;
2West German Cancer Center, Essen, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John J. Sunderland
5Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, Iowa; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janet H. Pollard
5Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, Iowa; and
6Department of Radiology, Iowa City Veterans Healthcare Center, Iowa City, Iowa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Semiautomatic total tumor segmentations with red overlay designating sites of segmented lesions in scans 1 and 2 for patient with disease limited to prostate and left pelvic lymph nodes (A) and patient with extensive skeletal metastases (B). Interval between scans was 2 d for both patients.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Examples of segmentation challenges on 68Ga-PSMA-HBED-CC PET/CT. Segmented tumor metastases are shown in red. (A) Metastasis in os ilium was segmented as single lesion on first scan but as 3 separate lesions in second scan (encircled). (B) Metastasis in rib was segmented accurately on first scan but inaccurately on second scan, with isocontour including portion of lung (encircled). Error was resolved manually.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Analysis of individual manually segmented 68Ga-PSMA-HBED-CC–avid lesions. Linear regression and Bland–Altman plots (A and B) of MTVlesion show correlation between scans. (C) Association is noted between MTVlesion and SUVmax changes between scans 1 and 2.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Analysis of semiautomatic whole-body segmentation of 68Ga-PSMA-HBED-CC–avid lesions. Linear regression (A and C) and Bland–Altman plots (B and D) of MTVtotal and mean SUVmax show excellent correlation between scans and suggest no association between total tumor volume or lesion intensity and test–retest differences. Results for readers 1 and 2 were averaged for purposes of these graphs. (A and C) MTVtotal and mean SUVmax for scan 1 are plotted separately against same metric for scan 2. (B and D) Mean of MTVtotal or mean SUVmax between scans 1 and 2 was plotted against absolute difference in metric between 2 scans.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Graphical analysis of intra- and interreader agreement in reporting MTVtotal, showing high correlation in measures between scans 1 and 2 for same reader (reader 1) (A) and showing high correlation in measures between 2 independent readers for same scan (scan 1) (B).

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Graphical analysis of prostate-specific antigen vs. MTVtotal, with log–log plot showing moderate correlation.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1.

    Patient Characteristics and MTVtotal Reported for Each Scan and Reader

    MTVtotal (mL)
    Patient no.PSA within ≤90 d (ng/mL)Gleason score at diagnosisR1, scan 1R2, scan 1R1, scan 2R2, scan 2
    10.157 (4 + 5)0000
    24.356 (3 + 3)4.815.884.815.88
    3104.59 (4 + 5)395.7404.02399.18402.22
    40.149 (4 + 5)59.9162.5982.4266.9
    50.669 (5 + 4)6.426.775.187.56
    60.229 (5 + 4)3.784.673.784.67
    756.3Presumptive diagnosis38.8935.5941.3622.49
    895.57 (4 + 3)206.38247.85236.35221.08
    9276.39 (4 + 5)643.19741.4643.19642.43
    100.04Presumptive diagnosis0000
    110.649 (4 + 5)7.788.337.788.33
    122.8Lymph node biopsy31.4944.6830.5346.24
    1340.110 (5 + 5)464.53587.13552.7515.05
    1419.77 (3 + 4)18.8722.8318.8722.83
    152.5Bone biopsy2.261.962.261.96
    1654.19 (5 + 4)85.89102.692.386.56
    172.59 (5 + 4)21.7821.8122.2921.81
    182.59 (5 + 4)6.526.315.537.34
    • PSA = prostate-specific antigen; R1 = reader 1; R2 = reader 2.

    • View popup
    TABLE 2.

    Repeatability of Manually Segmented Individual Lesions (MTVlesion)

    MetricwCV (%)RC (%)95% CI of RC (%)
    MTVlesion27.776.962.9–95.9
    PSMA-TLlesion23.364.753.4–80.67
    PSMA-TLQlesion34.595.781.5–114.5
    Lesion SUVmax12.434.429.6–41.2
    Lesion SUVpeak9.927.323.3–32.8
    Lesion SUVmean11.832.727.5–40.2
    • View popup
    TABLE 3.

    Repeatability of Manually Selected Lesion Subgroup per Patient (MTVsubgroup)

    MetricwCV (%)RC (%)95% CI of RC
    MTVsubgroup12.033.124.2–46.2
    Subgroup MTVmean12.033.124.8–47.7
    PSMA-TLsubgroup7.420.616.0–26.9
    PSMA-TLQsubgroup18.451.036.5–78.0
    Subgroup mean SUVmax12.334.020.0–59.4
    Subgroup mean SUVpeak6.618.313.3–24.5
    Subgroup mean SUVmean9.125.217.5–35.7
    • View popup
    TABLE 4.

    Repeatability of Semiautomatic MTVtotal per Patient

    MetricR1 wCV (%)R2 wCV (%)Mean wCV (%)R1 RC (%)R2 RC (%)Mean RC (%)95% CI of mean RC
    MTVtotal13.411.912.737.033.035.024.9–49.7
    Total MTVmean13.411.912.737.133.035.025.0–48.8
    PSMA-TLtotal8.412.110.323.333.528.420.7–41.9
    PSMA-TLQtotal19.417.318.453.948.050.932.7–84.7
    Total mean SUVmax8.48.68.523.323.923.617.0–32.4
    Total mean SUVmean8.18.08.122.622.222.416.4–30.7
    • R1 = reader 1; R2 = reader 2.

    • View popup
    TABLE 5.

    Repeatability of MTVtotal with Different Readers Between Scans

    MetricR1, R2 RC (%)R2, R1 RC (%)Mean RC (%)95% CI of mean RC
    MTVtotal29.944.737.327.9–49.3
    Total MTVmean29.944.737.329.9–44.7
    PSMA-TLtotal24.937.231.024.5–39.5
    PSMA-TLQtotal52.558.455.538.1–83.6
    Total mean SUVmax28.320.724.517.5–33.5
    Total mean SUVmean27.418.723.117.2–31.1
    • R1, R2 = first scan read by reader 1, second scan read by reader 2; R2, R1 = first scan read by reader 2, second scan read by reader 1.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (5)
Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Repeatability of 68Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Repeatability of 68Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
Robert Seifert, Patrick Sandach, David Kersting, Wolfgang P. Fendler, Boris Hadaschik, Ken Herrmann, John J. Sunderland, Janet H. Pollard
Journal of Nuclear Medicine May 2022, 63 (5) 746-753; DOI: 10.2967/jnumed.121.262528

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Repeatability of 68Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
Robert Seifert, Patrick Sandach, David Kersting, Wolfgang P. Fendler, Boris Hadaschik, Ken Herrmann, John J. Sunderland, Janet H. Pollard
Journal of Nuclear Medicine May 2022, 63 (5) 746-753; DOI: 10.2967/jnumed.121.262528
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
  • The VISION Forward: Recognition and Implication of PSMA-/18F-FDG+ mCRPC
  • Google Scholar

More in this TOC Section

  • Designed Ankyrin Repeat Protein–Mediated Peptide Nucleic Acid–Based Pretargeting: A Proof-of-Principle Study
  • [11C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B
  • Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model
Show more Basic Science Investigation

Similar Articles

Keywords

  • PSMA PET
  • tumor volume
  • repeatability
SNMMI

© 2025 SNMMI

Powered by HighWire